HCW Biologics Inc.

For the period ended Dec 31, 2024. Filed Mar 28, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 28, 2025

HCWB$0.95-6.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Changes in Stockholders’ Equity (Deficit)

	Stockholders’ Equity (Deficit)
Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Deficit	Equity (Deficit)
Balance, January 1, 2023	35,876,440	$3,588	$82,962,964	$(45,538,046)	$37,428,506
Issuance of Class A Common Stock upon exercise of stock options	148,664	15	23,724	—	23,739
Stock-based compensation	—	—	1,003,749	—	1,003,749
Net loss	—	—	—	(24,994,277)	(24,994,277)
Balance, December 31, 2023	36,025,104	$3,603	$83,990,437	$(70,532,323)	$13,461,717
Issuance of Common Stock upon exercise of stock options	13,473	1	2,443	—	2,444
Issuance of Common Stock upon equity subscription	1,785,718	178	2,499,827	—	2,500,005
Issuance of Common Stock	4,160,000	416	2,452,249	—	2,452,665
Issuance of warrants	—	—	4,465,589	—	4,465,589
Exercise of pre-funded warrants	2,557,000	256	—	—	256
Issuance cost of common stock	—	—	(226,201)	—	(226,201)
Issuance costs of common stock warrants	—	—	(411,844)	—	(411,844)
Stock-based compensation	—	—	1,009,011	—	1,009,011
Net loss	—	—	—	(30,023,814)	(30,023,814)
Balance, December 31, 2024	44,541,295	$4,454	$93,781,511	$(100,556,137)	$(6,770,172)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.